These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19373011)

  • 21. HIV-1 and intestinal helminth review update: updating a Cochrane Review and building the case for treatment and has the time come to test and treat?
    Alexander PE; De P
    Parasite Immunol; 2009 Jun; 31(6):283-6. PubMed ID: 19493207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues.
    Aït-Khaled N; Alarcon E; Bissell K; Boillot F; Caminero JA; Chiang CY; Clevenbergh P; Dlodlo R; Enarson DA; Enarson P; Ferroussier O; Fujiwara PI; Harries AD; Heldal E; Hinderaker SG; Kim SJ; Lienhardt C; Rieder HL; Rusen ID; Trébucq A; Van Deun A; Wilson N
    Int J Tuberc Lung Dis; 2009 Aug; 13(8):927-35. PubMed ID: 19723371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteopenia and osteoporosis in HIV: pathogenesis and treatment.
    Chew NS; Doran PP; Powderly WG
    Curr Opin HIV AIDS; 2007 Jul; 2(4):318-23. PubMed ID: 19372906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes.
    Sawe FK; McIntyre JA
    Clin Infect Dis; 2009 Aug; 49(3):463-5. PubMed ID: 19569971
    [No Abstract]   [Full Text] [Related]  

  • 25. Brazilian HIV-infected population: assessment of the needs of endodontic treatment in the post-highly active antiretroviral therapy era.
    de Brito LC; da Rosa MA; Lopes VS; e Ferreira EF; Vieira LQ; Sobrinho AP
    J Endod; 2009 Sep; 35(9):1178-81. PubMed ID: 19720212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Public-sector ART in the Free State Province, South Africa: community support as an important determinant of outcome.
    Wouters E; Van Damme W; Van Loon F; van Rensburg D; Meulemans H
    Soc Sci Med; 2009 Oct; 69(8):1177-85. PubMed ID: 19692165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance and viral subtypes: how important are the differences and why do they occur?
    Brenner BG
    Curr Opin HIV AIDS; 2007 Mar; 2(2):94-102. PubMed ID: 19372873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of opportunistic DNA viral infections by multiplex PCR among HIV infected individuals receiving care at a tertiary care hospital in South India.
    Sachithanandham J; Ramamurthy M; Kannangai R; Daniel HD; Abraham OC; Rupali P; Pulimood SA; Abraham AM; Sridharan G
    Indian J Med Microbiol; 2009; 27(3):210-6. PubMed ID: 19584500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies.
    Mallon PW
    Curr Opin HIV AIDS; 2007 Jul; 2(4):282-92. PubMed ID: 19372900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Building laboratory infrastructure to support scale-up of HIV/AIDS treatment, care, and prevention: in-country experience.
    Abimiku AG;
    Am J Clin Pathol; 2009 Jun; 131(6):875-86. PubMed ID: 19461097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early antiretroviral therapy: the role of cohorts.
    Sabin CA
    Curr Opin HIV AIDS; 2009 May; 4(3):200-5. PubMed ID: 19532051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity of HIV protease inhibitors: clinical considerations.
    Boesecke C; Cooper DA
    Curr Opin HIV AIDS; 2008 Nov; 3(6):653-9. PubMed ID: 19373038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The current and future situations of TB/HIV (co-infection of tuberculosis and HIV) in Japan].
    Yamada N; Nagai H
    Kekkaku; 2009 Apr; 84(4):203-11. PubMed ID: 19425395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in CD4 cell enumeration in resource-poor countries.
    Baum LL; Crowe S; Landay AL
    Curr Opin HIV AIDS; 2007 May; 2(3):234-40. PubMed ID: 19372892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of Earth Observation (EO) technologies in supporting implementation of the Ramsar Convention on Wetlands.
    MacKay H; Finlayson CM; Fernández-Prieto D; Davidson N; Pritchard D; Rebelo LM
    J Environ Manage; 2009 May; 90(7):2234-42. PubMed ID: 18462862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initiating antiretroviral treatment in a resource-constrained setting: does clinical staging effectively identify patients in need?
    Torpey K; Lartey M; Amenyah R; Addo NA; Obeng-Baah J; Rahman Y; Suzuki C; Mukadi YD; Colebunders R
    Int J STD AIDS; 2009 Jun; 20(6):395-8. PubMed ID: 19451324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Tanzania experience: clinical laboratory testing harmonization and equipment standardization at different levels of a tiered health laboratory system.
    Massambu C; Mwangi C
    Am J Clin Pathol; 2009 Jun; 131(6):861-6. PubMed ID: 19461095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging technologies in point-of-care molecular diagnostics for resource-limited settings.
    Peeling RW; McNerney R
    Expert Rev Mol Diagn; 2014 Jun; 14(5):525-34. PubMed ID: 24784765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initiation of antiretroviral therapy.
    Pozniak A
    Curr Opin HIV AIDS; 2006 Sep; 1(5):398-408. PubMed ID: 19372839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune reconstitution disease of the central nervous system.
    Torok ME; Kambugu A; Wright E
    Curr Opin HIV AIDS; 2008 Jul; 3(4):438-45. PubMed ID: 19373003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.